In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years
Authors: Gaetano Santulli
Journal: Annals of Internal Medicine (2018)

ACP Journal Club18 December 2018In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 yearsGaetano Santulli, MDGaetano Santulli, MDEinstein College, Montefiore University Hospital, New York, New York, Federico II University, Naples, Italy (G.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2018-169-12-067 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-39. https://pubmed.ncbi.nlm.nih.gov/30146931Clinical Impact RatingsGIM/FP/GP: Cardiology: Endocrinology: References1 McNeil JJ, Wolfe R, Woods RL, et al; ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509-18. [PMID: 30221597] Google Scholar2 Gaziano JM, Brotons C, Coppolecchia R, et al; ARRIVE Executive Committee. Use of Aspirin to Reduce Risk of Initial Vascular Events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036-46. [PMID: 30158069] Google Scholar3 Bibbins-Domingo K; U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:836-45. [PMID: 27064677]. Google Scholar4 Saini SD, Schoenfeld P, Fendrick AM, Scheiman J. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med. 2008;168:1684-90; [PMID: 1869508] Google Scholar5 Zaccardi F, Rizzi A, Petrucci G, et al. In vivo platelet activation and aspirin responsiveness in type 1 diabetes. Diabetes. 2016;65:503-9. [PMID: 26470782] Google Scholar6 Patti G, Cavallari I, Andreotti F, et al; Working Group on Thrombosis of the Italian Society of Cardiology. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol. 2018. [Epub ahead of print]. [PMID: 30250166]. Google Scholar Author, Article, and Disclosure InformationAffiliations: Einstein College, Montefiore University Hospital, New York, New York, Federico II University, Naples, Italy (G.S.)This article was published at Annals.org on 4 December 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021 18 December 2018Volume 169, Issue 12Page: JC67KeywordsAspirinCardiovascular diseasesDiabetes preventionHemorrhageHemorrhagic strokeIschemic strokeMyocardial infarctionNumber needed to harmSafetyTransient ischemic attacks ePublished: 18 December 2018 Issue Published: 18 December 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...